as 12-18-2024 9:47am EST
Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
Founded: | 1996 | Country: | Australia |
Employees: | N/A | City: | EASTWOOD SA |
Market Cap: | 6.3M | IPO Year: | 2021 |
Target Price: | $8.00 | AVG Volume (30 days): | 691.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.92 | EPS Growth: | N/A |
52 Week Low/High: | $0.18 - $1.60 | Next Earning Date: | 01-01-0001 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BNOX Breaking Stock News: Dive into BNOX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
GlobeNewswire
6 days ago
GlobeNewswire
9 days ago
GlobeNewswire
15 days ago
GlobeNewswire
16 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
MT Newswires
a month ago
The information presented on this page, "BNOX Bionomics Limited American Depository Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.